CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01736553
NCT01736553N/ACompleted
CompareCT.gov

Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development

Ohio State University·observational·Posted Nov 29, 2012·Updated May 4, 2018

In Brief

An observational study for Spinal Muscular Atrophy (SMA). Completed, enrolled 53 participants across 15 sites.

Detailed Summary

Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease. The primary study objective will be to identify prognostic and surrogate biomarkers of disease progression that will facilitate the execution of therapeutic SMA clinical trials in infants.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Muscular Atrophy (SMA)
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), Cure SMA, Massachusetts General Hospital, University of Iowa

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 29, 2012
Enrollment StartDec 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.6 years ago